The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

RAHWAY, N.J. - The U.S. Food and Drug Administration has accepted and granted priority review for Merck’s (NYSE:MRK) supplemental application seeking to update the label for WINREVAIR based on ...

RAHWAY, N.J., June 12, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced ...

RAHWAY, N.J. - Pharmaceutical giant Merck (NYSE:MRK), with a market capitalization of $203 billion and impressive 77% gross profit margin, will present new data from its HIV research pipeline at ...

Media: Kim Gorode 973-255-8094 [email protected] Investor: Peter Dannenbaum 908-740-1037 [email protected] ...

Editor’s note: This story was updated at 8:47 a.m. June 19, 2025, to note that Merck Manuals – a separate entity from Merck – launched the new tool.

RAHWAY, N.J., June 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety ...

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs Jun. 12, 2025 4:45 PM ET Merck & Co., Inc. (MRK) ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating ...

Heterogeneous Hippo pathway (YAP/TAZ) activation in lung adenocarcinoma drives tumor progression by enabling ferroptosis ...